Hepar

Hepar is an intravenous amino acid supplement containing a blend of essential and non‑essential amino acids including valine, alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine and proline. The product is marketed in the European Union and is intended for use in parenteral nutrition to support protein synthesis when oral intake is insufficient. No specific strength or dosage form is disclosed, currently available for clinical use.

Hepar is primarily indicated for patients requiring parenteral nutrition where oral or enteral feeding is not feasible. It is administered intravenously and integrated into individualized nutrition plans under medical supervision.

- Supplementation of essential amino acids in critically ill patients. - Support of nitrogen balance during prolonged fasting or surgery. - Provision of building blocks for tissue repair in burn or trauma care. - Adjunct to total parenteral nutrition regimens to meet protein requirements. - Use in metabolic disorders where specific amino acid deficiencies are identified.

Side‑effect profiles for Hepar reflect the typical observations associated with intravenous amino acid solutions. Most reactions are mild and resolve after discontinuation or with supportive measures.

Common: - Mild infusion site discomfort or erythema. - Transient nausea or mild gastrointestinal upset. - Temporary increase in serum urea nitrogen. - Mild electrolyte shifts, such as slight potassium changes. - Mild headache or dizziness during infusion.

Serious: - Anaphylactic or severe hypersensitivity reactions. - Significant metabolic acidosis. - Hyperammonemia in patients with liver dysfunction. - Severe electrolyte disturbances (e.g., hyperkalemia, hyponatremia). - Renal impairment manifested by reduced urine output in susceptible individuals.

When using Hepar, clinicians should observe several precautionary measures to minimize risk and ensure appropriate patient selection.

- Assess renal and hepatic function before initiating therapy. - Monitor serum electrolytes, especially potassium and sodium, during treatment. - Adjust dosage in patients with known metabolic disorders or amino acid deficiencies. - Avoid use in individuals with a documented hypersensitivity to any component of the formulation. - Ensure aseptic technique during intravenous administration to prevent infection. - Observe for signs of infusion-related reactions and pause the infusion if severe symptoms develop. - Document the total amount of amino acids administered to avoid exceeding recommended protein targets.

Hepar may interact with other intravenous therapies or metabolic agents; awareness of potential interactions helps maintain safety.

Avoid: - Concurrent administration with high‑dose potassium chloride solutions, which may exacerbate hyperkalemia. - Co‑infusion with other amino acid mixtures that could lead to excessive nitrogen load. - Avoid simultaneous infusion with calcium-containing solutions, which may precipitate amino acid complexes.

Use with caution: - Use cautiously with nephrotoxic drugs, monitoring renal function closely. - Combine with insulin therapy, as amino acids can stimulate insulin release and affect glucose control. - Concurrent use with diuretics may alter electrolyte balance; regular monitoring is advised. - When combined with corticosteroids, monitor for potential catabolic effects on protein metabolism.